STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRVO
  4. [8-K] CervoMed Inc. Reports Material Event

CervoMed (NASDAQ: CRVO) receives UK ILAP Innovation Passport for DLB drug

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

CervoMed Inc. announced that its lead candidate neflamapimod has been granted an Innovation Passport, allowing entry into the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for development in dementia with Lewy bodies (DLB). ILAP is designed to accelerate time to market and facilitate patient access through coordinated input from the MHRA, NHS and health technology assessment bodies.

Neflamapimod is an oral small molecule that selectively inhibits the alpha isoform of p38 MAP kinase to target neuroinflammation and synaptic dysfunction. It has been generally well tolerated across more than 800 Phase 1 and 2 participants and showed consistent signals of efficacy in the 91-patient Phase 2a AscenD-LB and 159-patient Phase 2b RewinD-LB DLB trials, improving cognitive and functional outcomes and key neurodegeneration biomarkers, with greatest benefits in patients without Alzheimer’s co-pathology. CervoMed has obtained alignment with the FDA and global regulators on a potential registration path in DLB, is focused on identifying a strategic partner and funding for a Phase 3 DLB trial, and is advancing Phase 2a programs in nfvPPA and ALS.

Positive

  • CervoMed’s lead candidate neflamapimod received an Innovation Passport under the UK ILAP for dementia with Lewy bodies, providing coordinated support from MHRA, NHS and HTA bodies that is designed to accelerate time to market and patient access in the UK.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Phase 2a AscenD-LB enrollment 91 patients Neflamapimod Phase 2a AscenD-LB trial in dementia with Lewy bodies
Phase 2b RewinD-LB enrollment 159 patients 16-week randomized, double-blind, placebo-controlled DLB trial
Extension period length 32 weeks Neflamapimod-only extension following the Phase 2b RewinD-LB trial
Participants across Phase 1 and 2 trials more than 800 participants Overall neflamapimod clinical development program safety and efficacy experience
nfvPPA biomarker data timing early fourth quarter of 2026 Planned interim biomarker readout from Phase 2a nfvPPA trial
First ALS patient dosing timing fourth quarter of 2026 Expected first patient dosing in EXPERTS-ALS Phase 2a trial
Innovation Passport regulatory
"Neflamapimod has been granted an Innovation Passport to enter the UK’s ILAP"
An innovation passport is a regulatory designation that identifies a promising new medical product and sets out a tailored, accelerated pathway for its development and review. Like a VIP pass that lets you skip slow lines, it gives developers earlier regulatory feedback and more flexible testing options, which can cut time and cost and reduce risk — factors investors watch because they can speed revenue and raise a product’s commercial value.
Innovative Licensing and Access Pathway regulatory
"entry into the UK’s Innovative Licensing and Access Pathway for development in DLB"
A regulatory and commercial route that lets a company secure rights to develop, approve, or distribute a medical product using faster, flexible, or non-traditional arrangements than standard pathways. Think of it as a shortcut lane negotiated with regulators, payers, or partners to test, license, or make a treatment available sooner under special conditions. It matters to investors because it can speed revenue timing, change cost and risk profiles, and affect the size and timing of market access.
dementia with Lewy bodies medical
"neflamapimod’s development in dementia with Lewy bodies (DLB)"
Dementia with Lewy bodies is a brain disorder characterized by progressive memory loss, confusion, and movement difficulties, similar to symptoms seen in Parkinson’s disease. It occurs when abnormal protein deposits, called Lewy bodies, develop in brain cells, disrupting their function. This condition matters to investors because it can impact healthcare needs, medication development, and the financial stability of related industries.
health technology assessment regulatory
"guidance from the MHRA, NHS, and health technology assessment bodies"
A health technology assessment is a systematic review that evaluates a medical product, test, or procedure for its clinical benefit, cost, and practical value to patients and health systems. Think of it as a detailed product review used by insurers and hospitals to decide whether to pay for or recommend a treatment; its conclusions strongly influence market access, pricing, and potential sales, so investors watch HTA outcomes as indicators of commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did CervoMed (CRVO) announce about neflamapimod in the UK?
CervoMed reported that its lead drug candidate neflamapimod was granted an Innovation Passport, enabling entry into the UK Innovative Licensing and Access Pathway for development in dementia with Lewy bodies, a progressive dementia with no approved treatments in the US or European Union.

What is the UK Innovative Licensing and Access Pathway (ILAP) cited by CervoMed (CRVO)?
The UK ILAP is a regulatory program that supports potentially transformative medicines addressing high unmet need. It offers an Innovation Passport, priority access to services, clinical trials support and coordinated MHRA, NHS and HTA guidance, all designed to accelerate time to market and patient access.

What clinical data support CervoMed (CRVO)’s neflamapimod program in DLB?
Neflamapimod has been tested in more than 800 participants across Phase 1 and 2 trials. In the 91-patient Phase 2a AscenD-LB and 159-patient Phase 2b RewinD-LB DLB studies, it improved dementia severity, cognitive and functional outcomes, and neurodegeneration biomarkers, with greatest benefit in patients without Alzheimer’s co-pathology.

What are CervoMed (CRVO)’s next development steps for neflamapimod in DLB?
CervoMed has obtained alignment with the FDA and global regulators on a potential registration path for neflamapimod in DLB. The company is focused on identifying a strategic partner and securing funding to advance the drug into a planned Phase 3 trial in dementia with Lewy bodies.

In which other indications is CervoMed (CRVO) developing neflamapimod?
Beyond DLB, neflamapimod is in development for recovery after ischemic stroke, primary progressive aphasia (including nfvPPA), and amyotrophic lateral sclerosis. A Phase 2a nfvPPA trial has completed enrollment, and the EXPERTS-ALS Phase 2a trial is expected to begin dosing patients in the fourth quarter of 2026.

What key risks and uncertainties does CervoMed (CRVO) highlight around neflamapimod?
CervoMed notes risks related to available cash resources, the need to secure additional funding and a DLB Phase 3 partnership, clinical trial outcomes, potential regulatory approvals, intellectual property protection, and broader economic and geopolitical conditions, any of which could cause results to differ from current expectations.
false 0001053691 0001053691 2026-08-04 2026-08-04
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
 
FORM 8-K
___________________________
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
August 4, 2026
Date of Report (Date of earliest event reported)
___________________________
CervoMed Inc.
(Exact name of registrant as specified in its charter) 
___________________________
Delaware
 
001-37942
 
30-0645032
(State or other jurisdiction 
of incorporation) 
 
(Commission 
File Number) 
 
(I.R.S. Employer 
Identification No.) 
 
 
 
 
 
20 Park Plaza, Suite 424
Boston, Massachusetts
 
02116
(Address of principal executive offices) 
 
(Zip Code) 
 
Registrant’s telephone number, including area code: (617) 744-4400
 
Not applicable
(Former name or former address, if changed since last report) 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Title of each class 
 
Trading 
Symbol(s) 
 
Name of each exchange 
on which registered 
Common Stock, $0.001 par value
 
CRVO
 
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐ 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 
 
 
 
Item 7.01         Regulation FD Disclosure
 
On August 4, 2026, CervoMed Inc. (the “Company”) issued a press release announcing that neflamapimod has been granted an Innovation Passport to enter the United Kingdom’s Innovative Licensing and Access Pathway for neflamapimod’s development in dementia with Lewy bodies. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
 
The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
 
Item 8.01         
 
The information set forth in the first and fourth paragraphs of the Company’s press release issued on August 4, 2026, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
 
Item 9.01         Financial Statements and Exhibits
 
(d)         Exhibits
 
Exhibit No.
 
Description
99.1
 
Press Release, issued August 4, 2026
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: August 4, 2026         
CervoMed Inc.
 
 
 
 
 
 
By:
/s/ William Elder
 
 
Name:
William Elder
 
 
Title:
Chief Financial Officer & General Counsel
 
 

Exhibit 99.1

 

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of

Dementia with Lewy Bodies (DLB)

 

Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines

 

Neflamapimod selected for the ILAP by joint consensus — recognized for being an innovative therapy that addresses a condition of high unmet need, with the demonstrated potential to offer a major therapeutic advantage in DLB treatment

 

Program provides CervoMed with early and coordinated guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA), the National Health System (NHS), and health technology assessment (HTA) bodies

 

 

BOSTON, August 4, 2026 — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that neflamapimod, its oral, small molecule drug candidate targeting neuroinflammation-driven disease processes underlying degenerative disorders of the brain, has been granted an Innovation Passport to enter the UK’s ILAP for neflamapimod’s development in DLB. Focusing on potentially transformative investigational treatments that address unmet clinical needs, the ILAP is designed to accelerate time to market and facilitate patient access to new medicines in the UK.

 

“We’re proud that neflamapimod has been granted entry into this unique and selective program, which recognizes both the highly significant need for an effective treatment for DLB and the transformative potential of neflamapimod for people with DLB and their families,” said Dr. Mark De Rosch, Ph.D., Executive Vice President, Regulatory and Government Affairs, and Program Management of CervoMed. “Very few drugs have been granted this opportunity through the ILAP since the entry criteria into the program were revised and the scientific hurdle for receiving the designation was increased in early 2025. We look forward to working with the UK regulators, the HTA bodies, and all NHS partners as we prepare for our planned Phase 3 trial and work diligently to get neflamapimod to the patients who may benefit.”

 

 

"DLB is the second most common progressive dementia in older people in the UK, yet it remains poorly understood and is often misdiagnosed. It is encouraging for the DLB community to see an investigational treatment for this devastating disease included in a program like ILAP. We are hopeful that the coordination between MHRA, the HTA bodies, and the NHS can bring us closer to patients having access to the UK's first approved treatment for DLB," said Jacqui Cannon, Chief Executive of the Lewy Body Society.

 

The Innovation Passport designation provides access to a single integrated platform for sustained collaboration between biopharmaceutical companies and the ILAP Partners: the MHRA, NHS, the HTA bodies – the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the All Wales Therapeutics and Toxicology Centre (AWTTC), and the Department of Health Northern Ireland. This includes priority access to services such as clinical trials support and NHS engagement, to help speed up access for patients where current treatment options are limited or non-existent.

 

About Dementia with Lewy Bodies

 

DLB is the second most common progressive dementia after AD, affecting millions worldwide. Patients may experience a combination of decline in cognitive function, cognitive fluctuations, visual hallucinations, and sleep disorders, as well as motor symptoms similar to Parkinson’s disease. There are no approved treatments for DLB in the United States or European Union, and the current standard-of-care therapies only temporarily relieve symptoms.

 

About Neflamapimod

 

Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood-brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, recovery after ischemic stroke, and primary progressive aphasia.

 

In nonclinical studies, neflamapimod restored synaptic function within the basal forebrain cholinergic system, the brain region most affected in DLB. Across Phase 1 and 2 clinical trials involving more than 800 participants, the drug has been generally well tolerated and demonstrated consistent signals of efficacy. In the 91-patient Phase 2a AscenD-LB trial, neflamapimod significantly improved dementia severity and functional mobility in patients with DLB. Results from the 159-patient Phase 2b RewinD-LB trial, a 16-week randomized, double-blind, placebo-controlled trial followed by a 32-week neflamapimod-only extension, further supported neflamapimod’s potential to deliver meaningful clinical benefit, improving both cognitive and functional outcomes and showing positive effects on key markers of neurodegeneration, one by structural MRI and one a blood-based biomarker. Across both studies, the greatest benefits were observed in patients without AD co-pathology. Collectively, these findings underscore the therapeutic promise and scientific validity of neflamapimod as a potential treatment for DLB and other degenerative brain disorders.

 

 

About the Lewy Body Society

 

The Lewy Body Society was the first Lewy body dementia charity in Europe.

 

The charity campaigns for greater recognition and resources for Lewy body dementia, funding cutting-edge research projects at leading universities across the UK to improve the diagnosis, treatment and care of people living with Lewy body dementia and their families.

 

It also provides information, advice and support to people affected by Lewy body dementia and their caregivers, as well as healthcare professionals and decision-makers.

 

About CervoMed

 

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. CervoMed has obtained alignment with the FDA and global regulatory authorities on a potential registration path for neflamapimod in DLB, and the Company is currently focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

 

 

Forward-Looking Statements

 

This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the Company’s need to acquire sufficient funding (through a strategic partnership or otherwise) for any Phase 3 trial in patients with DLB; expectations with respect to regulatory submissions and potential approvals thereof related to neflamapimod, if any, in DLB or any other indication, including the impact, if any, of the Innovation Passport Designation on any future regulatory milestone or the timing thereof; the Company’s plan to focus on strategic partnering to advance neflamapimod into Phase 3 for DLB and the timing of entering into any such partnership, if at all; the therapeutic potential of neflamapimod in DLB, nfvPPA, amyotrophic lateral sclerosis, or any other indication, including the degree of sustainability of any therapeutic effects or any other treatment effects observed in any clinical trial on any clinical, biomarker, or other outcome measure; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of any Phase 3 trial in patients with DLB, the anticipated data readouts from the Company’s Phase 2a trial in nfvPPA and the anticipated dosing of the first patient with neflamapimod in the EXPERTS-ALS trial; and any other expected or implied benefits, results, or expectations, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients with DLB or in any other indication. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms or at all, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials; the Company’s ability to successfully enter into a partnership to advance neflamapimod into Phase 3 for DLB in a timely manner, on acceptable terms, or at all; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA or other regulators; the Company’s ability to maintain the intellectual property protection afforded by the Company’s patent portfolio; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the US Securities and Exchange Commission (SEC) on March 13, 2026, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.

 

Contacts

 

Media:
Biongage Communications

lisa.guiterman@gmail.com

202-330-3431

 

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Press Releases

Other Documents